Fig. 3From: Time and productivity loss associated with immunotherapy infusions for the treatment of melanoma in the United States: a survey of health care professionals and patientsAverage, minimum, and maximum time patients with melanoma spend per infusion visit by immunotherapy administered (A) by phase of the infusion visit and (B) by type of time loss on the day of infusionBack to article page